What is a Periodic Benefit-Risk Evaluation Report (PBRER)?
A Periodic Benefit-Risk Evaluation Report (PBRER) is a comprehensive pharmacovigilance document submitted by Marketing Authorization Holders (MAHs) to regulatory authorities to evaluate a medicine’s ongoing safety profile and its overall benefit-risk balance. The PBRER provides a structured analysis of new safety data collected during a defined reporting interval and determines whether the product’s benefits continue to outweigh its risks.
The format and requirements for PBRER are defined under guidelines issued by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), specifically ICH E2C(R2).
Purpose of a Periodic Benefit-Risk Evaluation Report (PBRER)
The primary purpose of a PBRER is to ensure continuous monitoring of a product’s safety throughout its lifecycle. It enables regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to assess whether any new risks have emerged and whether risk minimization measures remain effective.
A PBRER typically includes:- Worldwide marketing authorization status
- Summary of significant safety findings
- Evaluation of cumulative safety data
- Signal and risk evaluation
- Benefit evaluation (efficacy and effectiveness data)
- Integrated benefit-risk analysis
- Conclusions and regulatory actions, if required
Importance of PBRER in Pharmacovigilance
The PBRER is a critical component of post-marketing surveillance. It supports evidence-based regulatory decisions, including label updates, additional risk minimization measures, or, in rare cases, product withdrawal.
By systematically analyzing both risks and benefits, the PBRER ensures that patient safety remains the top priority while maintaining access to effective therapies.
Benefits of Periodic Benefit-Risk Evaluation Reports
- Strengthens global pharmacovigilance systems
- Ensures continuous benefit-risk monitoring
- Supports regulatory transparency and compliance
- Enhances patient safety and public health protection
In today’s regulatory environment, the Periodic Benefit-Risk Evaluation Report (PBRER) is essential for maintaining a medicine’s safe and effective use throughout its lifecycle.